U.S. markets closed

X4 Pharmaceuticals, Inc. (XFOR)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
7.63+0.18 (+2.42%)
At close: 4:00PM EDT
Sign in to post a message.
  • M
    MD
    Stanley - I bought shares of X4 in 2017 along side crossovers like Cormorant Asset Management. The valuation at time of merger was not what insiders at X4 thought the company would actually be worth in the public market. The idea was to make terms very attractive to both Arsanis and top notch blue chip crossovers/institutions who wanted large stakes in X4. Those with deep knowledge of X4’s assets understood that this would rapidly correct to an appropriate valuation once shares traded publicly - which is what we’re seeing now and will continue to see. Shares are tightly held by high quality institutions and insiders who understand that the odds of hitting phase 3 endpoints are very high. The phase 2 WHIM results were compelling and the FDA actually lowered the bar a bit for phase 3 endpoints making odds of success extremely high - much higher than your typical ph3 RD company. Keep in mind they also have oncology assets which will likely be co-developed with pharma partners. This company was co-founded by Henri Termeer and is run by former Genzyme execs. The company is very undervalued - I’m sure we’ll soon see high quality analyst coverage echoing my view. I would buy shares before that analyst coverage is released.
  • N
    Nick
    All,
    X4 is a great company that has X-Celgene guys on the board and X-Genzyme folks in the Operations. This will also gain institutional interest in the coming days/weeks. with the Reverse Split, the float is low so any institutional buying will impact the stock greatly as you saw on Friday. My take is X4 should garner a market cap of $500 Million to $1 Billion over the next year or so. So $60-$70 per share equates to $500 Million depending on how they treat warrants/options. Lot's of potential here and I think the next 1-3 months will show if institutions feel the same way.
  • J
    Jack Cassidy
    I can not understand the recent reduction in the short positions in XFOR The last 10 Q was not positive. Q3 had a larger loss than Q2 by about $2.3 million. The “Good Old Days” for XFOR was 2018. XFOR Q2 revenue of $3 million looks like an aberration. The S,G&A has grown from from $3.9 million to $5.6 million over the last year. Outstanding shares are up 3.5 million in one year. What does that mean to current shareholders when and if a turnaround occurs? Total equity over the last four quarters; $129.2, $118.8, $104.9, $89.7 all in millions.
  • t
    traviticus
    A lot of viewers and no comments.
  • B
    BIG T
    $ASNS conversation
    This is a Reverse merger 6 to 1 $ASNS new ticker tomorrow $XFOR
    https://www.globalbankingandfinance.com/x4-pharmaceuticals-completes-merger-with-arsanis/
    X4 Pharmaceuticals, Inc. (Nasdaq: XFOR, as of March 14, 2019), a clinical-stage biopharmaceutical company focused on the development of novel therapeutics
    X4 Pharmaceuticals, Inc. (Nasdaq: XFOR, as of March 14, 2019), a clinical-stage biopharmaceutical company focused on the development of novel therapeutics
    www.globalbankingandfinance.com
  • E
    Eagle Eye
    Is XFOR about to go parabolic like PHUN and ORGO in February? Set up is similar.
  • C
    Cruisechef
    https://finance.yahoo.com/news/x4-pharmaceuticals-receives-breakthrough-therapy-133000282.html
    Sounds very promising. I'm expecting this to start trading well very early today.
    X4 Pharmaceuticals, Inc. (XFOR), a clinical-stage biopharmaceutical company focused on the development of novel therapeutics for the treatment of rare diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough
    X4 Pharmaceuticals, Inc. (XFOR), a clinical-stage biopharmaceutical company focused on the development of novel therapeutics for the treatment of rare diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough
    finance.yahoo.com
    Bullish
  • M
    MD
    XFOR is currently very undervalued. Most Ph3 rare dz companies are valued around 500-600M. Clementia was at 600M before being acquired for 1.2B. XFOR deserves a higher multiple because has rare dz and oncology assets. XFOR will move higher on partnership news, high analyst PT and increased investor awareness of this companies revenue potential — peak sales just from WHIM syndrome (ph 3) is around 400-500M.
  • J
    Jack Cassidy
    XFOR is not looking good numbers wise
    Revenue is back to ZERO after one good quarter, what happened?
    Pre-tax income remains negative for last four quarters
    ($17.7M), ($10.8M), ($10.8M), ($15.1)
    No inventory, no trade receivables
    EPS consensus for next four quarters
    ($.73), ($.74), (.71), ($.69)
    How long do you have to wait to see positive EPS?
    I am short.
    Bearish
  • M
    Mary
    Finally PR but not so good :( Oh well one day I'll be one her Bragging about getting in at a low level :) My vision includes a C8 vette with the xfor plate :) If a tree drops in the forest and nobody is around ... is it heard. :) echoooo echooooo hahahaha
  • R
    Ross Perot
    Absolutely no interest in this stock......even though it looks like their product for WHIM will get through....nobody interested in companies working on cures for rare diseases these days.....
  • S
    Stanley
    XFOR management said $115 million valuation based on pipeline, last round of raise and milestones. Trading at 2x that now. OVERVALUED.
  • J
    Joseph
    What’s the deal with this stock? 1 yr price target of $20, but can’t seem to generate any excitement/movement — thoughts?
  • R
    Raymond
    I think that fact that it held 20 is a good sign
    Bullish
  • R
    Raymond
    Looks like it was a good, Im looking for a position
  • r
    richard
    xfor 's management is top notch Paula
    learned from the best, Henry T was her
    mentor,I have visited, the company and
    met with management ,,I am very excited
    about the future, buying more on pullback
    around 17.00,hope it never sees it again.
    I have bought shares thru maxim group
    on 2 occasions and also have some
    warrant coverage as well
  • E
    Emmanuel
    $QD conversation
    $XFOR X4 Pharmaceuticals Initiates Phase 1b Clinical Trial of Mavorixafor in Combination with Ibrutinib for the Treatment of Waldenström’s Macroglobulinemia (WM) https://blueequity.io/r/78666/MA-X4-PHARMACEUTICALS
    We’re on a mission to democratize financial analysis.
    We’re on a mission to democratize financial analysis.
    blueequity.io
  • J
    Jack Cassidy
    This is a tough puppy to love. The 8-K instead of 10-k is the first red flag. On the balance sheet there is a dearth of information as to the makeup of the Total Equity. It would be nice to know the paid in capital and the accumulated deficit. Those two numbers tell you a lot. Look at the number of shares outstanding and the trend. In the last year the weighted average number of outstanding shares has gone from 1,718,000 to 20,014,000. The total loss remains constant but how many shareholders do you have to share with when X 4 turns around? You have been significantly diluted!
    The number of shares has jumped 11.6 times.
    Bearish
  • r
    richard
    only thing that is going to make this stock is a runup to phase 3 results as well as positve results in there phase 3 for whim.Also looks like
    they are checking direction and focusing
    more on rare diseases,which is a great move
    going to be a long ride ,so have patience
  • H
    Henry
    gnpx is flying